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This review article covers the synthetic strategies, structural aspects, and host-guest properties of ruthenium metalla-assemblies,
with a special focus on their use as drug delivery vectors. The two-dimensional metalla-rectangles show interesting host-guest
possibilities but seem less appropriate for being used as drug carriers. On the other hand, metalla-prisms allow encapsulation and
possible targeted release of bioactive molecules and consequently show some potential as drug delivery vectors. The reactivity of
these metalla-prisms can be fine-tuned to allow a fine control of the guest’s release.The larger metalla-cubes can be used to stabilize
the formation of G-quadruplex DNA and can be used to encapsulate and release photoactive molecules such as porphins. These
metalla-assemblies demonstrate great prospective in photodynamic therapy.
1. Introduction
Anticancer platinum complexes dominate the field of metals
in cancer chemotherapy, mainly because of the considerable
research effort that followed the fortuitous discovery of the
anticancer property of cisplatin (Figure 1) in the late 1960s
[1]. Unfortunately, the use of cisplatin is restricted because
of severe dose-limiting side effects, which arise from the
indiscriminate uptake of the drug into all rapidly dividing
cells. Indeed the platinum atom is known to efficiently bind to
serum proteins, especially human serum albumin (HsA) [2].
Once inside cells, aquated cisplatin species willmainly bind at
the N7 position of guanine, leading to significant distortions
of the DNA helix [3]. These DNA lesions are thought to
prevent replication and transcription and ultimately to lead
to cellular apoptosis [3].
The severe side effects of cisplatin have led to a mas-
sive investigation into the cytotoxicity and genotoxicity
of platinum-based compounds, in order to elucidate their
molecular mechanisms and identify key biomolecular targets
for rational drug design [6–8]. In the 30 years since cisplatin’s
first approval for human use, only two compounds have been
approved worldwide (oxaliplatin and carboplatin, Figure 1)
and another three gaining marketing approval in individual
nations (Nedaplatin, Lobaplatin, and Heptaplatin) [4]. Cur-
rently, there are four mononuclear platinum drugs in various
stages of clinical trials, with two of these being close to clinical
recognition (satraplatin [9] and picoplatin [10]). Two other
drugs (ProLindac and Lipoplatin) [11–14] will become the
first polymer/liposomal-based platinum drugs on the market
if approved [4].
Synthesized and developed contemporarily to mononu-
clear platinum complexes, polynuclear platinum compounds
have received a great deal of attention [15]. One of these
compounds, triplatin tetranitrate (BBR3464, Figure 2) [5, 16,
17], has entered four consecutive phase II trials, three of them
unsuccessful, and the drug has never moved into phase III
[4]. The results of the remaining phase II clinical trial on
metastatic pancreatic cancer which started in 2001 have yet to
be published. However, it was reported that BBR3464 causes
so severe large dose-limiting side effects where themaximum
tolerated dose (MTD) in humans was considerably lower
than the MTD for all the platinum-based drugs currently
used in the clinic [18].
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Figure 1:The three platinum-based anticancer drugs, cisplatin, carboplatin, and oxaliplatin, which have gainedworldwidemarketing approval
for humans [4].
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Figure 2: Structure of the first polynuclear platinum compound, triplatin tetranitrate (BBR3464), that has entered clinical trials [5].
A challenge of anticancer treatment is the specific delivery
of the drugs in order to avoid deleterious effects on normal
cells. In fact, most of the inorganic anticancer drugs have
potent effects also on normal cells due to the strong similarity
of the mechanisms of growth regulation of normal cells as
compared to their transformed counterparts.
Recent developments in nanotechnology have aimed at
delivering anticancer drugs in tumor tissue via encapsulation
in the so-called drug delivery systems [19, 20]. The delivery
strategy of anticancer drugs is based upon the particular
structure of tumor neoangiogenic vessels that allow the
passive targeting or enhanced permeability and retention
effect (EPR effect) [21]. The addition of targeting moieties on
the surface of such drug delivery systems, such as specific
antibodies recognition moieties, can further enhance the
active targeting to tumor cells. As such, a lot of effort has been
put into the development of such systems that would alleviate
the inherent toxicity of platinum drugs and resistance issues.
Liposomes [22], polymers [23–25], dendrimers [26], organic
macrocycles [27], nanoparticles [28], viruses [29], and carbon
nanotubes [30, 31] have all shown promises as drug delivery
vehicles for platinum therapeutics.
Metalla-assemblies have started to attract considerable
attention, but these systems have remained relativity unex-
plored as drug delivery vectors [32]. The assembly of
transition-metal complexes with polydentate ligands to give
discrete supramolecular structures has been studied by sev-
eral groups. Pioneered by Fujita et al. [33] and developed
by several groups in the 1990s [34, 35], the combination
of 90∘ coordination building blocks and linear ligands to
form square (four metal centers bridged by four equivalent
bidentate ligands, Figure 3) and rectangular assemblies (four
metal centers bridged by ligands of different lengths) has been
widely explored.
A few years later, the same approach was used to
generate discrete three-dimensional assemblies [36–38]. So
far, a multitude of two- and three-dimensional structures
incorporating transitionmetals with square-planar geometry
have been synthesized [34, 39]. These molecular boxes have
been used to generate confined environments to encapsulate
guest molecules, to protect sensitive or unstable molecules,
to recognize and trap specific guest molecules, or to act as
microreactors for specific reactions [32].
Recently, dipalladium(II) molecular cages of the formula
[Pd
2
L
4
](X)
4
(L = 2,6-bis(pyridin-3-ylethynyl)pyridine; X =
BF
4
− or SbF
6
−) have been shown to encapsulate two cisplatin
molecules within their cavities (Figure 4) [40]. These cages
represent the first example of a discrete metalla-assembly
encapsulating a FDA-approved inorganic drug molecule.
Additionally, the [(cisplatin)
2
⊂ Pd
2
L
4
]4+ host-guest adduct
can be quantitatively disassembled upon the addition of
a competing ligand, releasing cisplatin in an acetonitrile
solution. This property, if extended to biological media,
is particularly appealing in the context of drug delivery,
as it would potentially enable the controlled release of an
encapsulated drug from themetalla-assembly. Unfortunately,
the drawback of these palladium assemblies is their lability in
water and accordingly their instability in biological media.
The cytotoxic effects of ruthenium compounds are known
since the mid-50s [41], but these compounds have mostly
remained disregarded, partly because of their poor water
solubility, and mostly because the discovery of the anti-
cancer properties of cisplatin in the mid-60s has inclined
the research towards platinum compounds. The potential of
ruthenium compounds as anticancer drugs has been revived
and really exploited only in the mid-80s, with the pioneer
work of Clarke on the activation by reduction assumption
(Figure 5) [42]. This assumption is based on the gener-
ally accepted statement that ruthenium(II) complexes are
more reactive than ruthenium(III) complexes. Ruthenium
complexes are therefore administered as much less active,
nontoxic ruthenium(III) compounds, which are reduced in
toxic ruthenium(II) complexes in cancer cells. Only in cancer
cells is a chemically reducing environment created, as a result
of increased metabolic rate. Scientists working in this field
often make a point of comparing ruthenium compounds
favorably to platinum compounds in terms of its analogous
ligand exchange abilities, lack of cross-resistance, and lower
toxicity [43–45].
Currently, two inorganicmonoruthenium(III) complexes
NAMI-A and KP1019 have shown remarkable activities
(Figure 6) [46, 47].Themorewater-soluble version ofKP1019,
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Figure 3: First metalla-square obtained by combining 90∘ coordi-
nation building blocks and linear ligands, adapted from [33].
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Figure 4: Molecular structure of [(cisplatin)
2
⊂ Pd
2
L
4
]4+, adapted
from [40].
the sodium salt termed KP1339 (Figure 6), has recently fin-
ished a successful clinical phase I trial, where excellent activ-
ity, especially against neuroendocrine tumors, was observed
[48].
Since the mid-1990s, half-sandwich ruthenium(II) com-
pounds have started to attract considerable attention [49]; in
particular, the RAPTA family was developed in the group of
Dyson [50–52], and the RM175 and ONCO4417 compounds
were developed in the group of Sadler (Figure 7) [53]. These
derivatives exhibit very promising characteristics in vitro
(RM175) and in vivo (RAPTA). The RAPTA complexes can
be considered noncytotoxic in vitro but show antimetastatic
activity and have indicated selectivity to cancer cells over
nontumor cells [51]. The RAPTA complexes are inactive
Cell membrane
Cytosol
Ru(III)
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Ru(III)
Ru(II)
active
Reduction
Nucleus?Uptake
Figure 5: Schematic representation of the postulated activation by
reduction mechanism, adapted from [42].
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Figure 6: Molecular structure of the inorganic ruthenium(III)
complexes: NAMI-A, KP1019, and KP1339.
against primary tumors, but they appear to reduce the
number and weight of metastasis cells. In the case of RM175,
it shows high levels of toxicity towards cancer cells, affecting
DNA via a parallel interaction, thus resulting in apoptosis
[53]. Similarly ONCO4417 was shown to induce apoptosis as
well as to halt cell reproduction in various cancer types [53].
As such, arene ruthenium metalla-assemblies have
started to attract attention as a potential new class of
drug delivery vector. In the following, we will cover some
synthetic and structural aspects of arene ruthenium metalla-
assemblies, as well as their drug delivery potential. To be
efficient, metalla-assemblies must exhibit certain stability
in order to achieve controlled drug release in the body. In
addition, the presence of arene ruthenium building blocks
can only be beneficial if selectivity for cancer cells is obtained.
A special emphasis has been placed on our contributions to
this field over the last years, but important inputs from other
groups will be also discussed.
2. Water-Soluble Arene Ruthenium Complexes
The water solubility of arene ruthenium complexes is known
for 40 years, thanks to Zelonka and Baird who studied the
behavior of the benzene rutheniumdichloride dimer in water
[54]. Indeed, upon dissolution of [(benzene)RuCl
2
]
2
in water,
they observed by 1H NMR spectroscopy the formation of
aqua species. The complete assignment of the signals was
established later [55] but confirmed the observation made by
Zelonka and Baird that arene ruthenium dichloride dimers
form aqua species in water without rupture of the arene
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Figure 7: Half-sandwich ruthenium(II) complexes: RAPTA, RM175, and ONCO4417.
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Figure 8: Aquation of arene ruthenium dichloride dimers.
ruthenium bond (Figure 8). With the stability of the arene
ruthenium bond in water being established, the chemistry
of arene ruthenium complexes in aqueous solution is now
flourishing [55–57].
2.1. Water-Soluble Arene Ruthenium Metalla-Rectangles. The
first arene rutheniummetalla-rectangle has been synthesized
by Yan et al. in 1997 [58]. It was shown that the dinu-
clear cation [{(𝑝-cymene)Ru(MeOH)}
2
(ox)]2+, 𝑝-cymene =
𝑝-𝑖PrC
6
H
4
Me, incorporating an oxalato (ox) bridging ligand
reacts with 4,4󸀠-bipyridine (bipy) to form in quantitative
yield the tetranuclear tetracationic metalla-rectangle [Ru
4
(𝑝-
cymene)
4
(ox)
2
(bipy)
2
]4+ (Figure 9). For ten years, this sim-
ple strategy to form metalla-assemblies did not find much
attention; however, it is now one of the methods of choice to
form arene ruthenium metalla-assemblies, and it remains a
milestone in the field.
In 2009, two groups independently prepared water-
soluble arene ruthenium metalla-rectangles in view of eval-
uating them as anticancer agents [59, 60]. Navarro and Barea
have combined hoxonato dinuclear 𝑝-cymene ruthenium
clips with bipy and phen (phen = 4,7-phenanthroline),
while Therrien and his coworkers have used various arenes
(𝑝-cymene and hexamethylbenzene), two different bridg-
ing ligands (2,5-dihydroxy-1,4-benzoquinonato = dhbq; 2,5-
dichloro-1,4-benzoquinonato = dcbq), with bipy and bpe
(bpe = 1,2-bis(4-pyridyl)ethylene), to obtain analogous struc-
tures. In both series, the tetracationicmetalla-rectangles were
found to be cytotoxic in vitro, showing activity in the 𝜇M
range against ovarian cancer cell lines. In addition, strong
interaction with DNA was demonstrated for the hoxonato
derivatives, thus confirming the biological relevance of arene
ruthenium metalla-assemblies [59].
Following these first studies, Chi, Stang and coworkers
have reported several analogous metalla-rectangles, each
N
NN
N
O O
O O
O O
O O
Ru
Ru
Ru
Ru
Figure 9: Molecular structure of the first arene rutheniummetalla-
rectangle, [Ru
4
(𝑝-cymene)
4
(ox)
2
(bipy)
2
]4+, adapted from [58].
being formed by combining dinuclear arene ruthenium clips
and bipyridyl connectors [39, 61–65]. The IC
50
values for
particular combinations of clips and connectors are in the
lower micromolar range, while others show poor activities.
However, at this stage, the parameters dictating the biological
activity of these metalla-rectangles remain unclear. It has
been suggested that the size and the nature of the connectors
are important factors, as well as the charge and lipophilicity
of the assembly [66]; however, replacing the arene ruthenium
units by other half-sandwich complexes showed almost no
impact on the activity [67, 68]. Clearly, these studies suggest
that the best combination of arenes, metals, and connectors
has yet to be found.
Advances in Chemistry 5
2.2. Water-Soluble Arene Ruthenium Metalla-Prisms and
Metalla-Cubes. In parallel to the development of metalla-
rectangles, three-dimensional metalla-assemblies have been
prepared following the same strategy [32], simply by replac-
ing the bidentate connectors by tridentate or tetradentate lig-
ands. For example, combining oxalato bridged dinuclear clips
with tridentate 2,4,6-tris(pyridine-4-yl)-1,3,5-triazine (tpt)
panels affords in excellent yield the metalla-prism [Ru
6
(𝑝-
cymene)
6
(ox)
3
(tpt)
2
]6+ (Figure 10), which was isolated as
its triflate salt [69]. Similarly, the octanuclear octacationic
metalla-cube, [Ru
8
(𝑝-cymene)
8
(ox)
4
(tpp)
2
]8+, was obtained
by combining oxalato bridged dinuclear clips with 5,10,15,20-
tetra(pyridin-4-yl)porphyrin (tpp) tetradentate panels [70].
Throughout the paper, metalla-prisms are defined as six
metal centers connected by two tridentate panels and three
bridging ligands, while metalla-cubes are defined as eight
metal centers connected by two tetradentate panels and four
bridging ligands.
Despite possessing a small cavity, with the Ru ⋅ ⋅ ⋅Ru sepa-
ration within these diruthenium oxalato clips being 5.5 A˚, no
guest molecules fit in the cavity of the metalla-prism [Ru
6
(𝑝-
cymene)
6
(ox)
3
(tpt)
2
]6+ due to strong 𝜋-stacking interac-
tions between the adjacent tpt panels. Therefore, a longer
metal ⋅ ⋅ ⋅metal distance was needed to allow metalla-prisms
and metalla-cubes to encapsulate guest molecules. In large
three-dimensional assemblies, a cavity capable of accommo-
dating guest molecules does not necessarily insure host-guest
chemistry: access to the cavity is critical for the host-guest
process to take place. Therefore, unless the assembly pos-
sesses the ability to assemble-disassemble at will in solution,
a sufficient portal size of the host is an essential feature [32].
2.3. Stabilization of the G-Quadruplex DNA Formation
Using Metalla-Cubes. In 2009, we have shown that
arene ruthenium metalla-cubes [Ru
8
(𝜂6-arene)
8
(tpp-M)
2
(dhbq)
4
]8+ (arene = toluene, 𝑝-cymene, hexamethylbenzene)
(Figure 11), connected by two 5,10,15,20-tetra(4-pyridyl)
porphyrin (tpp-2H)or 5,10,15,20-tetra(4-pyridyl) porphyrin-
Zn(II) (tpp-Zn) tetrapodal subunits, bind strongly to
telomeric and c-myc DNA. Their selectivity for quadruplex
over duplex DNA is very modest.This is likely a consequence
of the octacationic nature of the cubes, which will
increase their nonspecific binding to DNA via electrostatic
interactions. However, these arene ruthenium metalla-cubes
provide an interesting new family of complexes to stabilize
quadruplex DNA [71].
3. Encapsulation of Guest Molecules and
Host-Guest Properties
3.1. Encapsulation of Guest Molecules with Metalla-Rect-
angles. The ability of the metalla-rectangles [Ru
4
(𝑝-
cymene)
4
(N∩N)
2
(dhnq)
2
]4+ (N∩N = pyrazine, 4,4󸀠-
bipyridine, and 1,2-bis(4-pyridyl)ethylene; dhnq = 5,8-dihy-
droxy-1,4-naphthoquinonato) to host pyrene in solution has
been investigated (Figure 12) [72]. In the case of the smallest
metalla-rectangle [Ru
4
(𝑝-cymene)
4
(pyrazine)
2
(dhnq)
2
]4+,
N
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N
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Figure 10: Molecular structure of the arene ruthenium metalla-
prism, [Ru
6
(𝑝-cymene)
6
(ox)
3
(tpt)
2
]6+, adapted from [58].
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Figure 11: Molecular structure of the arene ruthenium metalla-
cubes, [Ru
8
(𝜂6-arene)
8
(tpp-M)
2
(dhbq)
4
]8+, adapted from [71].
no interaction between the metalla-rectangle and pyrene was
observed. However, in the case of the medium-sized metalla-
rectangle [Ru
4
(𝑝-cymene)
4
(4,4󸀠-bipyridine)
2
(dhnq)
2
]4+,
interactions occurred on the outside of the rectangular
assembly, while in the larger metalla-rectangle [Ru
4
(𝑝-
cymene)
4
(1,2-bis(4-pyridyl)ethylene)
2
(dhnq)
2
]4+, the pyrene
molecule was found inside the hydrophobic cavity of the
metalla-rectangle, thus giving rise to a host-guest system.
During this study, we exploited two-dimensional 1H-
DOSY NMR experiments to gain further insight into the
nature of the interactions involved between pyrene and the
metalla-rectangles. Diffusion-ordered spectroscopy (DOSY)
is a well-established NMR technique that allows separating
6 Advances in Chemistry
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Figure 12: Molecular structure of the arene ruthenium metalla-rectangles, [Ru
4
(𝑝-cymene)
4
(pyrazine)
2
(dhnq)
2
]4+ (a), [Ru
4
(𝑝-
cymene)
4
(4,4󸀠-bipyridine)
2
(dhnq)
2
]4+(b), and [Ru
4
(𝑝-cymene)
4
(1,2-bis(4-pyridyl))(ethylene)
2
(dhnq)
2
]4+(c), adapted from [72].
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Figure 13: DOSY 1H NMR spectra of pyrene, of the metalla-rectangle [Ru
4
(𝑝-cymene)
4
(1,2-bis(4-pyridyl)ethylene)
2
(dhnq)
2
]4+, and of
additional amounts of pyrene (1 to 3 equivalent) to a 4.0mM solution of [Ru
4
(𝑝-cymene)
4
(1,2-bis(4-pyridyl) ethylene)
2
(dhnq)
2
]4+dissolved
in CD
3
CN, adapted from [72].
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the NMR signals of different species according to their
diffusion coefficient [73, 74]. From the DOSY spectra, it
is evidenced that the diffusion constants of pyrene and of
the medium-sized metalla-rectangle [Ru
4
(𝑝-cymene)
4
(4,4󸀠-
bipyridine)
2
(dhnq)
2
]4+ are unaffected, when mixed together.
Therefore, the chemical shifts observed for the host and the
guest were attributed to outer interactions. On the other
hand, in the case of the larger metalla-rectangle [Ru
4
(𝑝-
cymene)
4
(1,2-bis(4-pyridyl)ethylene)
2
(dhnq)
2
]4+, the inter-
action with pyrene is totally different. The DOSY spec-
tra show that for a 1 : 1 mixture of pyrene and [Ru
4
(𝑝-
cymene)
4
(1,2-bis(4-pyridyl) ethylene)
2
(dhnq)
2
]4+ both dif-
fusion coefficients are almost equivalent at about 6.3 ×
10
−10m2 ⋅s−1 (Figure 13). Consequently, the pyrene appears to
be located in the hydrophobic cavity of [Ru
4
(𝑝-cymene)
4
(1,2-
bis(4-pyridyl)ethylene)
2
(dhnq)
2
]4+, which is in accordance
with the strong chemical shift observed for both species in
the 1H NMR spectra.
We have subsequently extended this first study to three
other guest molecules, anthracene, perylene, and coronene,
and used 9,10-dihydroxy-1,4-anthraquinonato (dhaq) and
6,11-dihydroxynaphthacene-5,12-dionato (dhtq) bridging
ligands in addition to 5,8-dihydroxy-1,4-naphthoquinonato
(dhnq) [75]. As observed with themetalla-rectangles [Ru
4
(𝑝-
cymene)
4
(pyrazine)
2
(dhnq)
2
]4+, [Ru
4
(𝑝-cymene)
4
(4,4󸀠-bip-
yridine)
2
(dhnq)
2
]4+, and [Ru
4
(𝑝-cymene)
4
(1,2-bis(4-
pyridyl) ethylene)
2
(dhnq)
2
]4+, the largest metalla-rectangles
incorporating 1,2-bis(4-pyridyl) ethylene linkers are able to
host an anthracene, pyrene, perylene, or coronene molecule
in their cavity, while the medium-sized metalla-rectangles
incorporating 4,4󸀠-bipyridine linkers are only able to
encapsulate anthracene. However, out-of-cavity interactions
are observed between these 4,4󸀠-bipyridine-containing
metalla-rectangles and pyrene, perylene, or coronene. In
contrast, the small pyrazine-containing metalla-rectangles
showed no interaction in solution with this series of planar
aromatic molecules. Using the largest metalla-rectangles,
the stability constants of association are comprised between
5.2 × 104 and 6.9 × 104M−1 which implies a strong affinity
between the metalla-rectangle and the aromatic molecule
but suggests no selectivity by the metalla-rectangle among
these guests.
3.2. Encapsulation of Guest Molecules with Metalla-Prisms
and Metalla-Cubes. As demonstrated with the metalla-
rectangles, the presence of a cavity cannot warrant encap-
sulation of guest molecules. This is also true with metalla-
prisms and metalla-cubes. Indeed, the smallest metalla-
prism capable of encapsulating guest molecules was [Ru
6
(𝑝-
cymene)
6
(tpt)
2
(dhbq)
3
]6+ with a Ru ⋅ ⋅ ⋅Ru separation of
approximately 7.6 A˚ within the dhbq clip and a Ru ⋅ ⋅ ⋅Ru
separation of approximately 13.2 A˚ through the tpt pan-
els. This cavity allows the encapsulation of triphenylene
derivatives such as hexahydroxytriphenylene and hexam-
ethoxytriphenylene, thus forming carceplex systems [76].
During these studies, we showed for the first time that the
formation of these carceplex systems can easily be monitored
by one-dimensional 1H-ROESY NMR experiments. Using
the ROESY experiment, estimation of the different host-
guest H ⋅ ⋅ ⋅H separations could be established from the NMR
data and the H ⋅ ⋅ ⋅H distances found by NMR were in good
agreement with the values obtained by single-crystal X-ray
structure analysis [76].
In 2008, we reported the ability of the rutheniummetalla-
prisms [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhbq)
3
]6+, [Ru
6
(𝑝-cym-
ene)
6
(tpt)
2
(dchq)
3
]6+, [Ru
6
(C
6
Me
6
)
6
(tpt)
2
(dhbq)
3
]6+, and
[Ru
6
(C
6
Me
6
)
6
(tpt)
2
(dchq)
3
]6+ to permanently encapsulate
square planar complexes and aromatic molecules [77]
(Figure 14). The assembly could be achieved in the presence
of large aromatic molecules such as pyrene, fluoranthene,
benzo[e]pyrene, triphenylene, or coronene to give the
corresponding inclusion systems [arom- atic⊂prism]6+.
Interestingly, pyrene could be encapsulated even if it
contains a functionalized aliphatic substituent; in this case
the aromatic moiety was included in the cage, while the
functionalized side arm stood out. These findings opened
a simple and straightforward access to the preparation of
arene ruthenium metalla-prismatic cages able to encapsulate
aromatic and functionalized aromatic molecules, thus
demonstrating that they will find applications as drug
delivery containers [77].
Subsequently, the capacity to permanently encapsulate
large planar molecules as well as to allow host-guest chem-
istry to take place with smaller aromatic molecules was
demonstrated with a slightly more spacious metalla-prism
[Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhnq)
3
]6+ (Figure 15) [78]. All sta-
bility constants of association (𝐾a) determined by NMR
spectroscopy were found to be larger than 2.4 × 104M−1
for the host-guest systems with pyrene, phenanthrene, and
(pyren-1-ylmethyl)amine. On the other hand, using Pt(acac)
2
and triphenylene, only carceplexes were obtained.
These studies were extended to two larger cationic
metalla-prisms, namely, [Ru
6
(𝑝-cymene)
6
(tpt)
2
(doaq)
3
]6+
and [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dotq)
3
]6+ (Figure 16). The addi-
tion of one equivalent of phenanthrene, pyrene, triphenylene,
or coronene during the preparation of the metalla-prism
leads to the direct encapsulation of the aromatic molecule
[79]. Interestingly, both metalla-prisms exhibited host-guest
properties in solution only in the presence of small aromatic
molecules (phenanthrene and pyrene). However, for larger
aromatic molecules (triphenylene and coronene) capable of
fitting into the cavity but too large to exit the portal of the
cage, permanent encapsulation was observed, thus giving rise
to stable carceplex systems.
4. Drug Delivery
4.1. Encapsulation and Release of Bioactive Molecules. The
molecular recognition properties coupled with the promis-
ing biological activity of ruthenium assemblies suggested
that these compounds could potentially act as drug deliv-
ery vectors. We have first reported complex-in-a-complex
systems, in which platinum or palladium acetyl acetate
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Figure 14: Synthesis of metalla-prisms, [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhbq)
3
]6+, [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dchq)
3
]6+, [Ru
6
(hexamethylben-
zene)
6
(tpt)
2
(dhbq)
3
]6+, and [Ru
6
(hexamethylbenzene)
6
(tpt)
2
(dchq)
3
]6+, and molecular structure of the corresponding host-guest systems,
adapted from [78].
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]6+, adapted from [79].
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⊂ Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhbq)
3
]6+, adapted from [81].
complexes were encapsulated in the cavity of the metalla-
prism (Figure 17) [80]. The guest complexes by themselves
are biologically inactive due to their insolubility in aqueous
media. The metalla-prism and host-guest systems, which are
on the other hand both water-soluble, are shown to possess
high cytotoxic activity [80]. This and subsequent studies to
monitor the in vitro release of fluorescent pyrene-based guest
molecules, whose fluorescence is suppressed when encap-
sulated within the metalla-assembly, have shown that the
water-soluble metalla-prism is capable of being internalized
by cancerous cells and subsequently broken down to release
the hydrophobic guest molecules, which would otherwise
have been unable to enter the cells [81].
This first success has encouraged us to further
investigate these metalla-prisms as drug delivery vectors.
Monosubstituted pyrenyl derivatives were also encapsulated
in the metalla-prism [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhbq)
3
]6+
and the drug delivery ability of the resulting host-
guests systems was evaluated [81]. The pyrenyl derivatives
included biologically relevant structures, especially pyrenyl
ethacrynic, a derivate of ethacrynic acid, and 2-(pyren-1-
ylmethylcarbamoyl) phenyl acetate, the corresponding acid
chloride of aspirin (Figure 18). Ethacrynic acid is notably
known as an inhibitor of glutathione transferase (GST)
[83, 84]. The host-guest nature of these systems with the
pyrenyl moiety being encapsulated in the hydrophobic cavity
of the cage with the functional groups pointing outwards
was confirmed by NMR spectroscopy. All the host-guest
systems are more cytotoxic than the empty cage alone, the
most active carceplex being an order of magnitude more
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Figure 19: Fluorescence recorded by flow cytometry of the metalla-prism [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhnq)
3
]6+(A) and of 1-(4,6-dichloro-
1,3,5-triazin-2-yl)pyrene encapsulated in the metalla-prisms [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhnq)
3
]6+(B), [Ru
6
(𝑝-cymene)
6
(tpt)
2
(doaq)
3
]6+ (C),
and [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dotq)
3
]6+(D), indicating pyrene-R released from the host (blue bars). Ruthenium uptake determined by ICP-MS
is also shown (red bars). A2780 cells were incubatedwith themetalla-prism [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhnq)
3
]6+andwith pyrene-R encapsulated
in the three metalla-prisms at 2𝜇m concentration for 24 h, adapted from [82].
cytotoxic. This in vitro study revealed that the nature of the
pyrenyl derivative strongly influences the cytotoxicity of the
system and consequently confirms that these metalla-cages
offer a strategy to deliver biologically relevant molecules to
cancer cells [81].
Subsequently, the host-guest properties of a series of
larger metalla-prisms [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhnq)
3
]6+,
[Ru
6
(𝑝-cymene)
6
(tpt)
2
(doaq)
3
]6+, and [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dotq)
3
]6+ having similar sized cavities but different
portal sizes have been studied [82]. These metalla-prisms
are able to encapsulate the fluorescent guest molecule
1-(4,6-dichloro-1,3,5-triazin-2-yl)pyrene (pyrene-R) and
the complex Pd(acac)
2
. Remarkably, the rate of release of
the guest molecule is found to depend on the portal size
of the host, as shown by flow cytometric analysis of cells
incubated with the pyrene-R encapsulated in the three
metalla-prisms (Figure 19). It can be seen that the ratio
between cell fluorescence and the intracellular ruthenium
concentration varies as a function of the metalla-cage used
to entrap the pyrene-R fluorophore.
Nevertheless, the uptake of ruthenium into the cells deter-
mined by inductively coupled plasma mass spectroscopy
Advances in Chemistry 11
O O
O
O O
O
O O
O
O
Cl
Cl
+ AgCF3SO3
− AgCl
2+
Not isolated
+
tpt
CH2Cl2, RT
6+
OR
OR
OR
OR
OR
OR
CN
ROO CO2
CO2
Ru
Ru
Ru
Ru Ru
Ru
Ru
Ru
Ru
Ru
N
N
N
N
N N
N
N
N
N
N
N
N
NN
N
N
N
O O
O O
O O
O O
O O
OO
O
OO
O
= P0, P1, P2
[Pn ⊏ cage]
6+
P0 P2P1
(CH2)10O
O
O
O
O
O
O O
O
R = –(CH2)10O
Figure 20: Encapsulation of pyrenyl-functionalized dendrimers into the cavity of the metalla-prism [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhnq)
3
]6+.
(ICP-MS) reveals that all compounds enter the cells to
essentially the same extent, suggesting a similar uptake
mechanism for the three supramolecular complexes. Fur-
thermore, confocal microscopy showed that the pyrene-R
stains vesicle like cytoplasmic organelles and accumulates
in the intracellular vesicle of the cell endocytotic system.
A comparison between the fluorescence patterns of pyrene-
R with known fluorescent reporters showed that the free
pyrene-R does not enter lysosomal compartments and does
not accumulate in the endocytic compartments, which sug-
gest that pyrene-R accumulates in the endocytic rather
than the lytic compartments. Through the use of specific
inhibitors and fluorescent reporters, we have shown that
endocytosis is probably involved in the uptake and leads
to the accumulation of the guest molecule in intracellular
organelles.
Lately, we have been interested in the synthesis of
host-guest systems composed of water-soluble arene ruthe-
niummetalla-prisms and pyrenyl-functionalized dendrimers
(Figure 20) [85–87]. Dendrimers with defined structures
are well established and have been studied as potential
drug delivery vectors [26]. In particular, water-soluble and
biodegradable dendrimers are quite promising, as they have
been shown to improve drug solubility, to increase drug
circulation time, and to prolong drug residence in tumors.
We have first reported the synthesis and cytotoxicity of
host-guest systems composed of water-soluble arene ruthe-
niummetalla-prisms and pyrenyl-functionalized dendrimers
[86]. These studies showed that the host-guest systems
inhibit the growth of both sensitive and cisplatin resistant
cancer cells (A2780 and A2780cisR) with IC
50
values signif-
icantly lower than those of the empty metalla-prisms. The
dendrimers show no cytotoxic effects on these cell lines,
presumably owing to their poor solubility in water. However,
for the first time, this study has shown that metalla-cage host
systems are able to deliver large hydrophobic guest molecules
into cancer cells.
Subsequently, we have synthesized different genera-
tions of biodegradable water-soluble dendrimers based on
12 Advances in Chemistry
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Figure 21: Biodegradable water-soluble dendrimers encapsulated in the cavity of the metalla-prisms [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhnq)
3
]6+and
[Ru
6
(𝑝-cymene)
6
(tpt)
2
(dotq)
3
]6+[85].
the bis-MPA monomer functionalized by a pyrenyl unit
[87]. The aromatic part of the pyrenyl-functionalized den-
drimers could be encapsulated into the hydrophobic cav-
ity of the metalla-prisms [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhnq)
3
]6+
and [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dotq)
3
]6+ (Figure 21). Remark-
ably, the cytotoxicity of the resulting host-guest systems (IC
50
values ranging from 0.3 to 4.1 𝜇M) was considerably greater
than that of the individual hosts (IC
50
values 3.1 and 4.1 𝜇M)
and guests (IC
50
values 5.9 and 8.7 𝜇M). The enhanced
cytotoxicity of the host-guest systems compared to the guest
or host alone implies that intact host-guest systems are
entering the cells together and are responsible for the overall
cytotoxicity observed. Notably, the host-guest system is also
quite stable in biological media. These features, combined
with the potential of water-soluble dendrimers guests within
ruthenium metalla-prism hosts to preferentially accumulate
in tumors,make them interesting candidates for further study
and development.
4.2. Encapsulation and Release of Photosensitizers. Photo-
dynamic therapy (PDT) of cancer is a very powerful and
efficient method to treat diseases [88, 89], but the treatment
is potentially hampered by several aspects, one of the most
problematical being the chemical nature of the photosen-
sitizers [90]. Indeed, photosensitizers such as porphyrins
and phthalocyanines are in general poorly water-soluble,
unless highly substitutedwith hydrophilic groups, and exhibit
generally a low selectivity for cancer cells.
The development of vector-mediated selective drug deliv-
ery strategies is a major challenge in PDT. As such, encapsu-
lation of the photosensitizer within the hydrophobic cavity
of water-soluble carriers provides an elegant strategy to
transport photosensitizers in aqueous media.
Using the metalla-prism [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhnq)
3
]6+ and a larger octanuclear metalla-cube [Ru
8
(𝑝-
cymene)(dhnq)
4
(tpvb)
2
]8+ (tbpv = 1,2,4,5-tetrakis {2-(4-
pyridyl) vinylbenzene)} (Figure 22), both water-soluble, we
could demonstrate that porphin was encapsulated in the
metalla-cages and subsequently delivered intracellularly
[91–93]. As expected, the release of porphin is higher for the
larger cubic cage as compared to the smaller prismatic cage.
Interestingly, both systems display hypochromism properties
toward the photosensitizer when encapsulated inside the
cavity, resulting in the absence of phototoxic effect when
inside the cavity. This ability demonstrates that the cages
can be considered as powerful tools for new photodynamic
strategies.
Subsequently, we have reported an extension of
this work by studying the host-guest properties of the
metalla-prisms [Ru
6
(𝑝-cymene)
6
(tris-pvb)
2
(OO∩OO)
3
]6+,
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6
(𝑝-cymene)
6
(tpt)
2
(dhnq)
3
]6+and the larger octanuclear
metalla-cube [Ru
8
(𝑝-cymene)(dhnq)
4
(tpvb)
2
]8+.
OO∩OO = oxalato, dhbq, dcbq, dhnq, doaq, and
donq (Figure 23), and of the metalla-cubes [Ru
8
(𝑝-
cymene)
8
(NN∩NN)
2
(OO∩OO)
4
]8+ (NN∩NN = 1,2,4,5-
tetrakis{2-(pyridin-4-yl)vinyl}benzene, 1,2,4,5-tetrakis{2-
(pyridin-4-yl)ethynyl}benzene), OO∩OO = oxalato, dhbq,
dcbq, dhnq, doaq, and donq) (Figure 24) [91]. The photos-
ensitizers porphin, phthalocyanine, and Zn-phthalocyanine
present during the synthesis of these metalla-cages are
encapsulated in several of these arene ruthenium complexes
to give photosensitizer-encapsulated systems. NMR analysis
indicates that the guest photosensitizers are completely
encapsulated in two of these metalla-cages, while in
three other ruthenium cages the NMR spectra reveal an
equilibrium between empty and filled metalla-cages.
5. Reactivity of Arene Ruthenium
Metalla-Prisms
As mentioned in the previous parts, the expected function of
these rutheniummetalla-assemblies is the selective release of
an encapsulated drug in cancer cells. In principle, carceplexes
as well as host-guest systems could be used to achieve
this goal. However, both systems have inherent advantages
and drawbacks that should be first considered. In carceplex
systems, the guest molecule is expected to remain encap-
sulated in the metalla-assembly until the host-guest system
reaches its final target. The drawbacks of carceplex systems
are therefore directly related to the stability of the metalla-
assembly in biological media. If the stability of the metalla-
assembly is insufficient, the guest molecule will be released in
an uncontrolled manner within the human body and at sites
where the guest molecule is not necessarily needed, leading
potentially to a general toxicity and to undesired side effects.
Likewise, if the stability of themetalla-assembly is excessively
high, the selective release of an encapsulated drug at the
desired sites might last too long or may even never occur if
the metalla-assembly remains intact.
The advantages and drawbacks of host-guest systems
are similar to those of the carceplex systems, with the
additional problem of controlling the exchange rate of the
encapsulated molecule. Indeed, if the rate of exchange is too
fast, reactions between the encapsulated molecule and the
body’s molecular components (proteins, amino acids, and
lipids) cannot be avoided and most importantly cannot be
controlled. Furthermore, because a guest molecule might
well react with its surroundings within human bodies, the
probability that the guest molecule reenters into the cavity
of the metalla-assembly is significantly reduced. On the con-
trary, if the rate of exchange is too slow, the selective release
of an encapsulated drug in cancer cells will be excessively
long or even be completely suppressed if the exchange rate
approaches zero.
According to our recent findings, it turns out that con-
trolling the exchange rate of a guest molecule encapsulated in
a ruthenium metalla-assembly is a demanding task. Indeed,
to obtain a suitable exchange rate between the assembly and
the guest molecule, that is, to design a host-guest system that
would be able to release the target molecule at the desired
site and at the desired time interval, a fine tuning of both
structures of the metalla-assembly and of the guest molecule
is required. For those reasons, we believe that, for selectively
releasing an encapsulated drug in cancer cells, carceplex
systems appear more appropriate than host-guest systems.
Thus, in order to gain new insights into uptake, release of the
guest, and the other biological processes, we have started to
monitor reactions of various ruthenium metalla-prisms with
biological targets. Since all host-guest systems studied so far
are more cytotoxic than the empty assemblies themselves,
these studieswere also useful for understanding their possible
mechanisms of action.
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Figure 23: Encapsulation of various photosensitizers into the cavities of the metalla-prisms [Ru
6
(𝑝-cymene)
6
(tris-pvb)
2
(𝜇
2
-Cl)
6
]6+ and
[Ru
6
(𝑝-cymene)
6
(tris-pvb)
2
(OO∩OO)
3
]6+, OO∩OO = oxalato, dhbq, dcbq, dhnq, doaq, and donq, adapted from [94].
5.1. Reactivity against Amino Acids and Proteins. Various
experiments were undertaken in our groups to establish
the nature of the species that are effectively transported
into the cell, possible mechanisms of detoxification, and
further information on the cellular target that may be
related to the antitumor activity of the metalla-prisms.
Our first results showed that the metalla-prism [Ru
6
(𝑝-
cymene)
6
(tpt)
2
(dhbq)
3
]6+ specifically interacts with the thiol
groups of Cys and GSH and with the basic side chains of
His, Lys, and Arg but remains surprisingly inert upon the
addition of Met [94]. The results suggest that the reaction
of the metalla-prism [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhbq)
3
]6+ with
Arg, His, and Lys takes place within a few minutes with
quantitative release of the tpt and dhbq ligands. As a plausible
mechanism, Arg, His, and Lys may first coordinate to the
ruthenium atom via one of the basic groups of the side chain
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Figure 24: Encapsulation of various photosensitizers into the cavities of the cages [Ru
8
(𝑝-cymene)
8
(NN∩NN)
2
(OO∩OO)
4
]8+, NN∩NN
= 1,2,4,5-tetrakis{2-(pyridin-4-yl)vinyl}benzene, 1,2,4,5-tetrakis{2-(pyridin-4-yl)ethynyl}benzene), OO∩OO = oxalato, dhbq, dcbq, dhnq,
doaq, and donq, adapted from [94].
inducing the quantitative release of the tpt moiety. Through
this first coordination, the two Ru-O bonds between the
ruthenium atom and dhbq are released by the carboxylato
and the amino groups of the amino acid which can act
as second and third ligands, thus forming N,N,O- or N,O-
chelate adducts (Figure 25).
Interestingly, the larger metalla-prism [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhnq)
3
]6+ appears to be significantly more stable than
the metalla-prism [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhbq)
3
]6+ and is
disassembled in the presence of Arg, His, and Lys after 12 h
of incubation [95]. Moreover, the reaction with His was not
complete, since only 14%ofHis reacted aftermore than 1week
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3
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of incubation. Our results suggest that the metalla-prism
[Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhnq)
3
]6+ which is more robust
than metalla-prism [Ru
6
(𝑝-cymene)
6
(tpt)
2
(dhbq)
3
]6+ may
remain intact in the bloodstream and, therefore, may enter
cancer cells undamaged.
Our results obtained with these ruthenium metalla-
prisms seem to corroborate a recent study by Hanif et
al. [96], which suggests an inverse correlation between
metallo-drug protein interaction and cytotoxicity against
tumor cells. Indeed, similar to the metalla-prism [Ru
6
(𝑝-
cymene)
6
(tpt)
2
(dhnq)
3
]6+ (IC
50
= 0.45 𝜇M against A2780
cells), themetalla-prism [Ru
6
(𝑝-cymene)
6
(tpt)
2
(oxalato)
3
]6+
(IC
50
= 0.93 𝜇M against A2780 cells) reacts relatively slowly
and incompletely with biomolecules [97]. The less cytotoxic
assembly (IC
50
= 0.96 𝜇M against A2780 cells), [Ru
6
(𝑝-
cymene)
6
(tpt)
2
(dhbq)
3
]6+, on the other hand, reacts rather
quickly with biomolecules, and a complete and fast disassem-
bly could be observed with Arg, His, and Lys.
5.2. Tuning/Controlling the Reactivity. As shown in the pre-
vious sections, ruthenium assemblies must exhibit a cer-
tain degree of stability, in order to selectively release the
encapsulated drug in the cancer cells and not in the cytosol.
As discussed, the stability of metalla-assemblies is a central
criterion and should be sufficient; otherwise the drug might
be released in an uncontrolled manner within the human
body.The stability should also not be excessive; otherwise the
drug might remain encapsulated and the host-guest system
might spread in an uncontrolled manner within the human
body.
Our results suggest a connection between the linkers
used and the reactivity of the resulting metalla-assembly.
To further investigate this hypothesis, studies of other arene
ruthenium assemblies bearing bulkier ligands such as hex-
amethylbenzene instead of 𝑝-cymene, or ruthenium assem-
blies with more sterically hindered linkers, are currently
undertaken. The possible correlation between reactivity and
cytotoxicity for these new arene ruthenium assemblies and
their host-guest properties will be investigated in the near
future.
6. Conclusion
In this review article, strategies applied to obtain tetranuclear
metalla-rectangles, hexanuclear metalla-prisms, and octanu-
clearmetalla-cubes and their host-guest properties have been
extensively described. As shown along this review, some of
these systems show great potential for host-guest chemistry
and for biological applications.The straightforward synthetic
strategy can be easily exploited and adapted to build up
other supramolecular ruthenium assemblies for encapsulat-
ingwater-insoluble bioactivemolecules and photosensitizers.
We are further extending this concept to arene-osmium and
to rhodium and iridium half-sandwich complexes, to obtain
metalla-assemblies with different properties, such as stability,
solubility, and charge.We are also working on the synthesis of
stimuli-responsivemetalla-assemblies. Among external stim-
uli to initiate the release of guestmolecules, we can in particu-
lar envisage the use of light, pH, temperature, and chemicals.
In conclusion, the encapsulation of guest molecules in water-
soluble arene ruthenium metalla-assemblies allows the guest
molecule to reach cellular components and organelles that
would be otherwise inaccessible and opens new perspectives
for scientists.
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